Capstone Therapeutics Corp. (NASDAQ:CAPS) Short Interest Down 56.3% in September

Capstone Therapeutics Corp. (NASDAQ:CAPS) was the recipient of a large decline in short interest in September. As of September 15th, there was short interest totaling 99,200 shares, a decline of 56.3% from the August 31st total of 227,000 shares. Based on an average daily volume of 1,970,000 shares, the short-interest ratio is presently 0.1 days. Approximately 5.1% of the company’s shares are sold short. Approximately 5.1% of the company’s shares are sold short. Based on an average daily volume of 1,970,000 shares, the short-interest ratio is presently 0.1 days.

Capstone Therapeutics Stock Down 6.4%

Shares of NASDAQ:CAPS opened at $1.31 on Friday. Capstone Therapeutics has a 52 week low of $0.96 and a 52 week high of $16.18. The company has a quick ratio of 0.41, a current ratio of 0.97 and a debt-to-equity ratio of 0.22. The firm has a 50 day moving average price of $1.30.

Capstone Therapeutics (NASDAQ:CAPS) last announced its quarterly earnings results on Friday, August 15th. The company reported ($0.13) earnings per share for the quarter. The business had revenue of $12.85 million for the quarter.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the stock. Wall Street Zen upgraded shares of Capstone Therapeutics to a “sell” rating in a research report on Friday, June 6th. Weiss Ratings restated a “sell (d-)” rating on shares of Capstone Therapeutics in a research report on Saturday, September 27th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company presently has a consensus rating of “Sell”.

About Capstone Therapeutics

Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism.